期刊文献+

重型药疹的静脉注射用丙种球蛋白治疗

IVIG Treatment of Severe Drug Eruptions
下载PDF
导出
摘要 重型药疹是一种病情危重、死亡率较高的疾病。临床上以大面积皮肤和黏膜红斑、水疱,甚至糜烂、渗出为主要表现,常伴发各种感染、水/电解质代谢紊乱以及重要器官功能障碍等。抗生素、抗癫痫药、非甾体抗炎药为诱发重型药疹的常见药物。重型药疹的治疗包括大剂量糖皮质激素、静脉注射用丙种球蛋白(IVIG)以及环磷酰胺、环孢素、肿瘤坏死因子α拮抗剂、血液透析、血浆置换等。其中IVIG因其有效性和安全性而被广泛应用,但其疗效又缺乏完整的循证学证据支持。文中就IVIG治疗重型药疹的现况进行了概述,为更有效应用IVIG抢救重型药疹提供一定的参考。 Severe drug eruptions are serious and life-threatening diseases. Wide spread rash,bullae,erosion and exudation of skin and mucosa accompanied with infections,metabolic abnormalities,multiorgan dysfunction are their clinical manifestations. Antibiotics,anticonvulsants,and nonsteroidal anti-inflammatory drugs are the common causes of these diseases. systemic corticosteroids,immunoglobulins( IVIG),cyclosporine, cyclophosphamide, plasmapheresis,and tumor necrosis factor-alpha inhibitors could be employed as treatments. IVIG is widely used these days,but without complete randomized controlled trials supported. This review collected and analysised the literaturesof IVIG in the treatment of severe drug eruptions,aid to improve the treatmentof thesesevere diseases.
作者 曾抗 ZENG Kang(Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China)
出处 《中国医学文摘(皮肤科学)》 2016年第6期743-750,共8页 China Medical Abstracts(Dermatology)
关键词 静脉注射用丙种球蛋白 重症多形红斑型药疹 大疱性表皮松解型药疹 药物超敏反应综合征 重型药疹 Immunoglobulin Stevens-Johnson syndrome Toxic epidermal necrolysis Drug hypersensitivity syndrome Severe drug eruptions
  • 相关文献

参考文献5

二级参考文献42

  • 1李常兴,张锡宝,吴志华.静脉用免疫球蛋白在皮肤科临床的应用及进展[J].国外医学(皮肤性病学分册),2005,31(3):171-173. 被引量:16
  • 2胡成,吴建华,顾军.重症药疹24例临床分析[J].中国皮肤性病学杂志,2006,20(11):680-680. 被引量:9
  • 3Bastuji-Garin S, Rzany B, Stem RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol, 1993, 129 ( 1 ): 92-96.
  • 4Bastuji-Garin S, Fouchard N, Bertocehi M, et al. SCORTEN: a severity of illness score for toxic epidermal neerolysis. J Invest Dermatol, 2000, 115(2): 149-153.
  • 5Imahara SD, Holmes JH, Heirnbaeh DM, et al. SCORTEN Overestimates Mortality in the Setting of a Standardized Treatment Protocol. J Burn Care Res, 2006, 27(3 ): 270-275.
  • 6Cartotto R, Mayich M, Nickerson N, et al. SCORTEN Accurately Predicts Mortality Among Toxic Epidermal Neerolysis Patients Treated in a Burn Center. J Bum Care Res, 2008, 29 (1): 141-146.
  • 7Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN During the First Five Days of Hospitalization to Predict the Prognosis of Epidermal Necrolysis. J Invest Dermatol, 2006, 126(2): 272-276.
  • 8Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol, 2004, 140(7): 890- 892.
  • 9Liddell FD. Simple exact analysis of the standardized mortality ratio. J Epidemiol Community Health, 1984, 38( 1 ): 85-88.
  • 10Khalili B, Bahna SL. Pathogancsis and recent therapoutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol, 2006, 97(3 ): 272-280.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部